A follow-up on active surveillance and the MEAL study

A couple of weeks ago, the full report on the Men’s Eating and Living (MEAL) study was published in the Journal of the American Medical Association. It has generated a lot of discussion, some of which is distinctly misguided. … READ MORE …

Beyond PSMA — FAPI theranostics

Ideally, a new diagnostic and therapy (“theranostic”) will have the following qualities:

  • It will be theranostic for all cancers (high sensitivity)
  • It will not be theranostic of anything that isn’t cancer (high specificity)

… READ MORE …

Why lutetium-177-PSMA treatment sometimes may not help, and may even harm

Lu-177-PSMA usually improves survival

We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. … READ MORE … -p>

FDA approves enzalutamide for treatment of metastatic HSPC

Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …

Diabetes and risk for prostate cancer

There have long been suggestions that men already diagnosed with and receiving treatment for diabetes are at lower risk for a subsequent diagnosis of prostate cancer than non-diabetics. However, a very large, new, epidemiological analysis seems to suggest strongly that this may not be the case at all. … READ MORE …

Risk for prostate cancer in men under 40 years of age

A newly published paper by Blayer et al. in in the journal Cancer has stated that,

Worldwide, the incidence of prostate cancer has increased in all groups between ages 15 and 40 years and increased globally at a steady rate averaging 2% per year since 1990.

… READ MORE …

InfoLink information hiatus

Over the past month there have been no new postings to this web site. Your sitemaster apologizes for this hiatus.

The reasons are complex and include the sitemaster’s personal health status (nothing really serious but distinctly debilitating) and other business and personal pressures.

The current goal is to start to get things back on track as on Monday, November 18, so please be patient with us for just a couple more days.